This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sucampo Names Peter Greenleaf Chief Executive Officer

BETHESDA, Md., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced that Peter Greenleaf will join Sucampo as Chief Executive Officer ("CEO") and as a member of the Board of Directors ("Board") on March 3, 2014. Mr. Greenleaf, 43, brings to Sucampo more than 20 years of experience in commercialization and drug development in the biopharmaceutical industry.

Peter Greenleaf
Peter Greenleaf

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=23524

Ryuji Ueno, M.D., Ph.D., Ph.D. will step down as CEO, Chairman of the Board, and member of the Board when Mr. Greenleaf joins Sucampo. In addition, Dr. Ueno will step down as Chief Scientific Officer on March 31, 2014.  As Co-Founder, Chairman Emeritus, and Scientific Advisor, Dr. Ueno will provide consulting services to ensure a smooth transition and advise Sucampo on the development of its pipeline and other strategic activities, through a one-year, renewable contract.

In addition, Dan Getman, Ph.D. has been named Chairman of the Board, effective March 3, 2014. Dr. Getman has been a Director of Sucampo since 2011 and is the current Chairman of Sucampo's Science and Technology Committee, as well as Chairman and/or member of other Board committees.

"Peter's expertise in growing biopharmaceutical companies, including experience leading a gastroenterology business, will be a valuable addition to Sucampo. The Board is confident that under his leadership Sucampo's legacy of growth will be accelerated," said Dr. Getman. "Peter brings the right mix of commercial, strategic planning, and product development expertise that we believe will enhance the value of Sucampo's proprietary prostone technology and its delivery to patients and healthcare providers around the world. On behalf of the entire Board, I also want to thank Dr. Ueno for his visionary leadership and the strong scientific foundation he established for Sucampo. His breakthrough discovery of the therapeutic potential of prostones led to the development and approval of two products, and it established Sucampo as a global biopharmaceutical company whose medicines have benefited millions of patients across three continents."

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,881.77 -33.30 -0.20%
S&P 500 1,962.67 -2.01 -0.10%
NASDAQ 4,404.8330 +8.6290 0.20%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs